Latham & Watkins has advised Arcus Biosciences. Gunderson Dettmer has advised the underwriters. Arcus Biosciences, a clinical-stage, global biopharmaceutical company listed on the NYSE under the...
Arcus Biosciences Completes $287.5 Million Common Stock Offering
Realty Income’s Merger With Spirit Realty Capital
Latham & Watkins is acting as legal advisor to Realty Income, while Wachtell, Lipton, Rosen & Katz is acting as legal advisor to Spirit. Realty Income...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
IDEAYA Biosciences’ $175 Million Common Stock Public Offering
Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
Bending Spoons’ Acquisition of Evernote
Latham & Watkins represented Evernote in the transaction. Willkie advised Bending Spoons. Bending Spoons, a leading European technology company, has announced an agreement to acquire Evernote,...
Arcutis Biotherapeutics’ $150 Million Shares Offering
Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
Colonnade Acquisition Corp. II’s Business Combination with Plastiq
White & Case represented Colonnade, while Latham & Watkins represented Plastiq in the transaction. Colonnade Acquisition Corp. II, a special purpose acquisition company (NYSE: CLAA), announced...
Amgen’s $3.7 Billion Acquisition of ChemoCentryx
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
P3 Health Partners’ Business Combination with Foresight Acquisition Corp.
Latham & Watkins represented P3 Health Partners in the transaction. P3 Health Partners, a patient-centered and physician-led population health management company, has closed its previously announced business combination...
Vacasa’s $4.5 Billion De-SPAC Business Combination with TPG Pace Solutions
Latham & Watkins LLP represented Vacasa in the transaction, while Weil, Gotshal & Manges advised TPG Pace Solutions. Vacasa, the leading vacation rental management platform in...
Realty Income’s Merger With VEREIT
Latham & Watkins LLP represented Realty Income, while Wachtell, Lipton, Rosen & Katz represented VEREIT in the transaction. Realty Income Corporation (NYSE: O), The Monthly Dividend...